Al­con touts PhI­II win for dry eye drug, plans mid-2024 FDA fil­ing

Al­con is look­ing to file its top clin­i­cal can­di­date for FDA ap­proval mid-year af­ter clinch­ing pos­i­tive Phase III re­sults.

Its eye drop can­di­date, AR-15512, helped …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER